• Publications
  • Influence
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo.
Primary-progressive multiple sclerosis
A controlled trial of natalizumab for relapsing multiple sclerosis.
In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain
MTR is affected by myelin content in MS white matter, and the extent of gliosis was detected using morphometric and digital imaging techniques.
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.
Atrophy provides a sensitive measure of the neurodegenerative component of multiple sclerosis and should be measured in trials evaluating potential anti-inflammatory, remyelinating or neuroprotective therapies.
Clinically isolated syndromes
Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis
This study has demonstrated functionally relevant changes indicative of axonal loss and retinal ganglion cell loss in the RNFL and macula, respectively, after optic neuritis, and this noninvasive RNFL imaging technique could be used in trials of experimental treatments that aim to protect optic nerves from axonal losses.
Optic neuritis